Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

During a routine cardiovascular follow-up, a 65-year-old male patient is evaluated for long-term care planning. He was diagnosed with nonvalvular atrial fibrillation three weeks ago and subsequently initiated on apixaban for thromboembolic prevention. His medical history includes hypertension and stage 2 chronic kidney disease. His daily regimen consists of apixaban, lisinopril, and amlodipine. He denies any recent bleeding, unusual bruising, or palpitations. As part of guideline-directed medical therapy, which TWO of the following parameters must be included in his routine, long-term surveillance plan? (Select two)

  1. Assessment of serum creatinine and estimated glomerular filtration rate at least annuallyCevap
  2. Assessment of hemoglobin and hematocrit at least annuallyCevap
  3. C
    Routine monitoring of prothrombin time (PT) and international normalized ratio (INR)
  4. D
    Routine measurement of peak and trough anti-factor Xa levels
  5. E
    Serial transthoracic echocardiography every 6 months to confirm the absence of left atrial thrombus

Cevap

The necessary monitoring parameters are the assessment of serum creatinine and estimated glomerular filtration rate at least annually, and the assessment of hemoglobin and hematocrit at least annually.
Direct oral anticoagulants (DOACs) such as apixaban offer the advantage of predictable pharmacokinetics, thereby eliminating the need for routine monitoring of coagulation times. However, safe long-term use requires specific surveillance. First, because DOACs are partially eliminated via the kidneys, a decline in renal function can lead to drug accumulation and major bleeding; therefore, serum creatinine and estimated glomerular filtration rate (eGFR) must be evaluated at least annually (and more frequently in those with advanced age or established chronic kidney disease). Second, because these agents inherently disrupt hemostasis, patients are at risk for chronic, asymptomatic blood loss (particularly from the gastrointestinal tract). As a result, an annual complete blood count or assessment of hemoglobin and hematocrit is essential to detect occult bleeding early.

Adım Adım Çözüm

1
Identify the primary medication being evaluated and its drug class.
The patient is taking apixaban, which is a direct oral anticoagulant (DOAC) specifically targeting factor Xa.
Different classes of anticoagulants have distinct monitoring requirements and safety profiles.
2
Determine the clearance mechanisms and primary adverse effects associated with this medication class.
Apixaban is partially cleared by the kidneys, and like all anticoagulants, its primary adverse effect is bleeding.
Understanding pharmacokinetics and side effect profiles dictates what organ systems need routine surveillance.
3
Apply guideline-directed surveillance protocols for long-term DOAC therapy.
Guidelines mandate at least annual monitoring of renal function to ensure appropriate dosing, and annual hemoglobin/hematocrit monitoring to detect occult bleeding.
This ensures both continued efficacy (proper dosing) and patient safety over the course of lifelong therapy.

Anahtar Kavram

Patients receiving direct oral anticoagulants (DOACs) require at least annual monitoring of renal function to guide dosing adjustments and annual complete blood counts to screen for occult hemorrhage, but do not require routine coagulation testing.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru